Viamet Pharmaceuticals is looking for investors.

The Durham-based pharmaceutical startup is raising a third round of funding, according to an SEC filing.

Viamet says it has raised $3 million and wants $2.75 million more.

Six investors have put more money into the firm, which is backed by Durham-based Intersouth Partners.

The money was raised in a mix of equity, options and warrants. 

Viamet is developing technology it calls Metallophile to make drugs safer through use of so-called metalloenzyme inhibitors. The inhibitors are actual metal components of drugs and bind to other metals in a patient’s body, enabling drugs to work.

The startup was co-founded by UNC-CH Chancellor Holden Thorp.